VANCOUVER, March 8 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX)
announced today that President and Chief Executive Officer Dr. Fahar Merchant
will be presenting at the BioSquare 2007 conference to be held at the Lyon
Convention Centre in Lyon, France, March 12 to 14. Dr. Merchant's presentation
will provide an overview and update on recent developments at the company and
will take place on Tuesday, March 13 at 5:15PM in the Rhône 1 room.
BioSquare has become one of the premier international partnering events
in Europe bringing together biotech executive, industry leaders and investors
representing more than 800 life sciences companies from over 30 countries.
Protox Therapeutics is a leader in advancing novel, targeted protein
toxin therapeutics for treatment of cancer and other proliferative diseases.
The company is actively developing two distinct but complementary platforms,
INxin(TM) and PORxin, and currently has three clinical programs in
development. A Phase IIa clinical trial into the use of PRX321 (INxin) for the
treatment of primary brain cancer has been completed and the drug has received
Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a
Phase I trial has been completed for PRX321 to treat patients with renal cell
carcinoma and non-small cell lung cancer. Patient enrolment is underway for a
Phase I clinical study into the use of PRX302 (PORxin) to treat localized
prostate cancer. PRX302 has also been approved by Health Canada to commence a
Phase I clinical study for the treatment of benign prostatic hyperplasia.
NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS
RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
For further information:
For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 688-0199, email@example.com; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,